1887
  1. Home
  2. Eurosurveillance
  3. Volume 26, Issue 12, 25/Mar/2021
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

Sera were collected from 185 adults aged ≥ 70 years in London to evaluate the immune response to COVID-19 vaccines. A single dose of Pfizer/BioNtech vaccine resulted in > 94% seropositivity after 3 weeks in naïve individuals using the Roche Spike antibody assay, while two doses produced very high spike antibody levels, significantly higher than convalescent sera from mild-to-moderate PCR-confirmed adult cases. Our findings support the United Kingdom’s approach of prioritising the first dose and delaying the second dose of COVID-19 vaccine.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.12.2100329
2021-03-25
2024-12-31
/content/10.2807/1560-7917.ES.2021.26.12.2100329
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/12/eurosurv-26-12-1.html?itemId=/content/10.2807/1560-7917.ES.2021.26.12.2100329&mimeType=html&fmt=ahah

References

  1. GOV.UK. Optimising the COVID-19 vaccination programme for maximum short-term impact. London: Department of Health and Social Care; 2021. Available from: https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact
  2. Public Health England (PHE). Evaluation of the Abbott SARS-CoV-2 IgG for the detection of anti-SARS-CoV-2 antibodies. London: PHE; 2020. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/890566/Evaluation_of_Abbott_SARS_CoV_2_IgG_PHE.pdf
  3. Public Health England (PHE). Evaluation of Roche Elecsys AntiSARS-CoV-2 serology assay for the detection of anti-SARS-CoV-2 antibodies. London: PHE; 2020. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/891598/Evaluation_of_Roche_Elecsys_anti_SARS_CoV_2_PHE_200610_v8.1_FINAL.pdf
  4. Jeffery-Smith A, Dun-Campbell K, Janarthanan R, Fok J, Crawley-Boevey E, Vusirikala A, et al. Infection and transmission of SARS-CoV-2 in London care homes reporting no cases or outbreaks of COVID-19: prospective observational cohort study, England 2020. Lancet Regional Health - Europe. 2021;3:100038.
  5. Imperial College. Real-time Assessment of Community Transmission (REACT) Study. London: Imperial College. [Accessed: Mar 2021]. Available from: https://www.reactstudy.org/
  6. Harris RJ, Whitaker HJ, Andrews NJ, Aiano F, Amin-Chowdhury Z, Flood J, et al. Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. medRxiv. 2020.10.21.20216689. https://doi.org/ https://doi.org/10.1101/2020.10.21.20216689 .
  7. Public Health England (PHE). Weekly national Influenza and COVID-19 surveillance report. Week 8 report (up to week 7 data) 25 February 2021. London: PHE; 2021. Available from: https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports
  8. Abu Jabal K, Ben-Amram H, Beiruti K, Batheesh Y, Sussan C, Zarka S, et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill. 2021;26(6):2100096.  https://doi.org/10.2807/1560-7917.ES.2021.26.6.2100096  PMID: 33573712 
  9. Haute de Autorité de Santé. Une seule dose de vaccin pour les personnes ayant déjà été infectées par le SARS-CoV-2. [A single dose of vaccine for people who have already been infected with SARS-CoV-2]. Saint-Denis: Haute de Autorité de Santé; Feb 2021. French. Available from: https://www.has-sante.fr/jcms/p_3237456/fr/une-seule-dose-de-vaccin-pour-les-personnes-ayant-deja-ete-infectees-par-le-sars-cov-2
  10. Public Health England (PHE). PHE monitoring of the early impact and effectiveness of COVID-19 vaccination in England. London: PHE; 2021. Available from: https://www.gov.uk/government/publications/phe-monitoring-of-the-effectiveness-of-covid-19-vaccination
  11. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021;NEJMoa2101765.  https://doi.org/10.1056/NEJMoa2101765  PMID: 33626250 
  12. Whitaker HES, Rowe C, Otter A, Brooks T, Linley E, Hayden I, et al. Impact of COVID-19 vaccination program on seroprevalence in blood donors in England. London: Public Health England; Mar 2021. Available from: https://khub.net/documents/135939561/390853656/Impact+of+COVID-19+vaccination+programme+on+seroprevalence+in+blood+donors+in+England.pdf/20d4b611-fda8-e70a-05eb-b13deb816ebf?t=1616002462349
  13. Ward H, Cook G, Whitaker M, Redd R, Eales O, Brown JC, et al. REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England. medRxiv:2021.02.26.21252512. https://doi.org/ https://doi.org/10.1101/2021.02.26.21252512 
Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Sathyavani+Subbarao&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Subbarao Sathyavani</a>, <a href="/search?value1=Lenesha+A+Warrener&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Warrener Lenesha A</a>, <a href="/search?value1=Katja+Hoschler&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hoschler Katja</a>, <a href="/search?value1=Keith+R+Perry&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Perry Keith R</a>, <a href="/search?value1=Justin+Shute&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Shute Justin</a>, <a href="/search?value1=Heather+Whitaker&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Whitaker Heather</a>, <a href="/search?value1=Michelle+O%E2%80%99Brien&option1=author&noRedirect=true" class="nonDisambigAuthorLink">O’Brien Michelle</a>, <a href="/search?value1=Frances+Baawuah&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Baawuah Frances</a>, <a href="/search?value1=Paul+Moss&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Moss Paul</a>, <a href="/search?value1=Helen+Parry&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Parry Helen</a>, <a href="/search?value1=Shamez+N+Ladhani&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ladhani Shamez N</a>, <a href="/search?value1=Mary+E+Ramsay&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ramsay Mary E</a>, <a href="/search?value1=Kevin+E+Brown&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Brown Kevin E</a>, <a href="/search?value1=Gayatri+Amirthalingam&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Amirthalingam Gayatri</a></span>. Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021. <a href="/content/ecdc">Euro Surveill.</a> 2021;26(12):pii=2100329. <a href="https://doi.org/10.2807/1560-7917.ES.2021.26.12.2100329" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2021.26.12.2100329</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 15 Mar 2021;&nbsp;&nbsp; <span class="generated">Accepted</span>: 25 Mar 2021 </span> </p>
/content/10.2807/1560-7917.ES.2021.26.12.2100329
/content/10.2807/1560-7917.ES.2021.26.12.2100329
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error